Emergent BioSolutions [EBS] has acquired the assets and rights to a recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology from VaxGen, Inc. [VXGN] for $2 million plus a potential additional $8 million in milestone payments. The arrangement also includes specified percentages of future net sales. VaxGen's original $877 million contract to develop and produce a next-generation anthrax vaccine was terminated by the Department of Health and Human Services in December 2006 due to stability issues with the…
Recommended
Skunk Works Plans First Flight of Vectis Prototype By End of Next Year
Trending
Congress Updates
CBO Estimates Loss of One-Half to Two-Thirds of U.S. Missile Interceptors Since June Last Year
A new Congressional Budget Office report estimates the cost of the Iran war through Aug. 1 as $38 billion and says that the U.S. has likely depleted between one-half and […]
Fischer Says Golden Dome Boosters Need To Increase Capitol Hill Support With Information, Warns Against Counting On Reconciliation
NATIONAL HARBOR, Md. – A Senate Armed Services panel chair today said boosters of the Golden Dome program still have work to do to increase support on Capitol Hill while […]
HII Executive Outlines Its Shipbuilding Acceleration Strategy
An HII [HII] shipbuilding executive last week told lawmakers how the company plans to improve and accelerate shipbuilding throughout via workforce improvements, adding new shipbuilding infrastructure and reinforcing distributed shipbuilding […]
House Sends Dec. 11 CR With Ship Construction Funds To Trump’s Desk For Final Signature
The House on Tuesday passed a stopgap funding bill to keep the government open through Dec. 11, sending the temporary funding measure that also includes funds to support ongoing shipbuilding […]